Liraglutide injection bulk supplier for pharma manufacturers

Liraglutide Injection Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 6 mg/mL pen (up to 3 mg daily)

Reference Brands: Saxenda (US & EU), Victoza (USA)

Saxenda (liraglutide 3 mg) is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and increases satiety. It supports weight loss, improves metabolic health, and helps manage obesity. Benefits include appetite suppression, significant weight reduction, improved blood sugar control, and enhanced overall wellness.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Liraglutide Injection? List it or send an offer →

Product Description:

Saxenda (liraglutide 3 mg) is approved in the US by the FDA and in the EU via EMA for chronic weight management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety profiles, manufacturing standards, and pharmacovigilance plans. The FDA reviews trial and quality data promptly, while EMA ensures regional safety and manufacturing compliance. Proper adherence supports swift approval, safe administration, and global availability, helping patients worldwide achieve significant weight loss and metabolic health improvements through high-quality Saxenda therapy supported by regional regulations.

Liraglutide Injection — third party manufacturing & bulk supply

Liraglutide Injection is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Liraglutide Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Liraglutide Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Liraglutide Injection →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Chronic weight management, alongside diet and exercise, in adults with obesity or with overweight and a weight-related condition, and in adolescents aged 12 to 17 with obesity and body weight above 60 kg. It is sold by Novo Nordisk as Saxenda.

No. Both are 6 mg/mL pens. Saxenda is dosed up to 3 mg a day for weight management; Victoza up to 1.8 mg a day for type 2 diabetes.

Generic versions have been approved in some markets; in the US the first generic of Saxenda was approved in August 2025. We confirm registration status and availability for your market.

See our main liraglutide page for Victoza-type pens and liraglutide API, or send us an RFQ with the product and market.